Advertising
Showing 1 to 15 of 23 entries
DON'T BUY
A lottery ticket! The company has gone into orphan status. Have disappointed investors many, many times. They keep needing money. Very risky.
biotechnology / pharmaceutical
DON'T BUY
Trying to raise $50 million which is equivalent/more than their entire market cap.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick June 14/04. Down 56%.) They continue to lose money. They'll have to get something through their pipeline quickly that deals with cancer. Doesn't look good.
biotechnology / pharmaceutical
TOP PICK
Holds this stock personally. Risky could double.
biotechnology / pharmaceutical
VAGUE
A field that you have to be really wary of. Many of them have a very high burn rate. Although their trials were fast tracked, this does not necessarily mean continued success.
biotechnology / pharmaceutical
DON'T BUY
Have restructured and will need more money.
biotechnology / pharmaceutical
BUY
Very volatile. Developing a product for HBV (a sexually transmitted disease), which has a large market. In phase two. Has a partnership with Roach and has enough cash to probably last into 2005.
biotechnology / pharmaceutical
DON'T BUY
On their watch list. Lost a lot of maney last year.
biotechnology / pharmaceutical
BUY on WEAKNESS
A speculative stock. Has to move through the regulatory gateway. Meets a lot of technical resistance at the $1.81 level. Try to pick up near its support level of $1.25.
biotechnology / pharmaceutical
BUY
They are far enough into their trials that investors are now paying more attention. Relatively cheap. Management is OK.
biotechnology / pharmaceutical
BUY
Outlook is quite good and the price is at a good level.
biotechnology / pharmaceutical
BUY
At a good level. Has mad a good agreement with a large pharmaceutical.
biotechnology / pharmaceutical
WEAK BUY
In the final stage of their clinical trials. Will be a couple of years before you know if the product works.
biotechnology / pharmaceutical
WEAK BUY
Well along on the approval line. Product seems to be good. The sector is suffering. A higher risk.
biotechnology / pharmaceutical
WAIT
Fairly risky, but a good risk/reward ratio. In phase 3 trials. Could double if they get into a good partnership.
biotechnology / pharmaceutical
Showing 1 to 15 of 23 entries

Stressgen Biotechnologies Corp(SSB-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Stressgen Biotechnologies Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stressgen Biotechnologies Corp(SSB-T) Frequently Asked Questions

What is Stressgen Biotechnologies Corp stock symbol?

Stressgen Biotechnologies Corp is a OTC stock, trading under the symbol SSB-T on the (). It is usually referred to as or SSB-T

Is Stressgen Biotechnologies Corp a buy or a sell?

In the last year, there was no coverage of Stressgen Biotechnologies Corp published on Stockchase.

Is Stressgen Biotechnologies Corp a good investment or a top pick?

Stressgen Biotechnologies Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Stressgen Biotechnologies Corp.

Why is Stressgen Biotechnologies Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stressgen Biotechnologies Corp worth watching?

In the last year 0 stock analysts on Stockchase covered Stressgen Biotechnologies Corp. The stock is worth watching.

What is Stressgen Biotechnologies Corp stock price?

On , Stressgen Biotechnologies Corp (SSB-T) stock closed at a price of $.